NewAmsterdam Pharma develops obicetrapib, an oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol. It last closed at $19.39 on Nov 17, down 0.36% on the day. The average 12-month price target from 4 analysts is $50.25 (+159.2% from the last close), with a high of $61.00 and a low of $42.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in NAMS, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $1.6M, the largest $659K.
Each firm's latest rating on NAMS in the past 90 days
Average 12-month target
$50.25
▲ 159.2% upside
Based on 4 analysts who set a price target on NAMS in the past 90 days. The average target is $50.25, with a high of $61.00 and a low of $42.00, compared with the last close of $19.39.
Low $42.00Avg $50.25High $61.00
Blue marker: last close $19.39
Highest target$61.00
Average target$50.25
Lowest target$42.00
Latest rating changes
Cantor FitzgeraldMaintained
Nov 11Buy$61
NeedhamMaintained
Nov 5Buy$46
RBC CapitalTarget lowered
Oct 5Buy$50 → $42
HC Wainwright & Co.Reiterated
Sep 8Buy$52
RBC CapitalTarget lowered
Aug 6Buy$51 → $50
Date
Firm
Action
Rating
Price target
Nov 11
Cantor Fitzgerald
Maintained
Buy
$61
Nov 5
Needham
Maintained
Buy
$46
Oct 5
RBC Capital
Target lowered
Buy
$50 → $42
Sep 8
HC Wainwright & Co.
Reiterated
Buy
$52
Aug 6
RBC Capital
Target lowered
Buy
$51 → $50
Loading…
Technical Analysis
NAMS · as of the Nov 17 close · updated after every close
Downtrend
The stock is 3% below its 20 day and 10% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 43). The nearest support is the swing low (Oct 23) at $19.13, and the nearest resistance the Pivot at $19.53.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 6.8%/day
Key levels
$42.2152 week high+117.7%
$29.04200 day average+49.8%
$25.39100 day average+30.9%
$21.2850 day average+9.7%
$20.82Swing high (Nov 11)+7.4%
$20.16Pivot R1+4.0%
$20.0420 day average+3.4%
$19.53Pivot+0.7%
$19.39Last close
$19.13Swing low (Oct 23)−1.3%
$18.76Pivot S1−3.2%
$17.9052 week low−7.7%
Indicators
RSI (14)
43.26
Middle of its range
Neutral
MACD
-0.57
Above its signal line
Bullish
Stochastic
40.4
Middle of its range
Neutral
ADX (14)
15.0
No clear trend
Williams %R
-65.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-67.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−2.6%
Change over 10 sessions
Bearish
ATR (14)
$1.32
Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 16.0%/day
Key levels
$42.2152 week high+117.7%
$29.04200 day average+49.8%
$25.39100 day average+30.9%
$21.2850 day average+9.7%
$20.82Swing high (Nov 11)+7.4%
$20.16Pivot R1+4.0%
$20.0420 day average+3.4%
$19.53Pivot+0.7%
$19.39Last close
$19.13Swing low (Oct 23)−1.3%
$18.76Pivot S1−3.2%
$17.9052 week low−7.7%
Indicators
RSI (14)
33.31
Weak, oversold below 30
Neutral
MACD
-3.16
Below its signal line
Bearish
Stochastic
12.6
Near the bottom of its range
Oversold
ADX (14)
20.9
Weak trend
Williams %R
-86.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-89.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.0%
Change over 10 sessions
Bearish
ATR (14)
$3.10
Typical daily range, 16.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for NAMS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NAMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Whale flow leans bearish0 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow NAMS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NAMS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAMS is in one of them and how their past NAMS trades turned out.
NewAmsterdam Pharma is a biopharmaceutical company based in Naarden, Netherlands. It is developing obicetrapib, a once-a-day oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol who do not reach their targets on statins alone. The drug can be taken on its own or combined with ezetimibe, another cholesterol-lowering pill. The company plans to sell it in the United States itself and has given Menarini the rights to market it in most of Europe.